XellSmart Achieves FDA Clearance for Innovative Cell Therapies Addressing Major CNS Disorders
XellSmart Secures FDA Clearance for Novel Cell Therapies
XellSmart Biomedical Co., Ltd., a notable biotechnology firm based in Suzhou and Shanghai, China, has recently achieved a major milestone by securing FDA clearance for three phase I Investigational New Drug (IND) applications. These innovative therapies are aimed at addressing significant unmet needs in central nervous system (CNS) disorders, specifically targeting conditions such as Parkinson's disease (PD), spinal cord injury (SCI), and amyotrophic lateral sclerosis (ALS).
Breaking New Ground in Biomedicine
This achievement is a significant leap forward, as XellSmart has now successfully obtained seven IND approvals from both the U.S. Food and Drug Administration (FDA) and China’s National Medical Products Administration (NMPA). Each approval emphasizes the company’s commitment to developing clinical-grade, off-the-shelf iPSC-derived cell therapy candidates designed to treat some of the most pressing health challenges in the field of neurodegenerative diseases.
Parkinson's Disease
Parkinson's disease, which affects over 10 million individuals worldwide, is recognized as the second most common neurodegenerative disorder. XellSmart's therapies have undergone phase I clinical trials in both the United States and China, demonstrating promising potential for alleviating symptoms in patients. The company's prior clinical studies in this arena achieved remarkable results, with clinical-grade iPSC-derived dopaminergic neural progenitor cells being utilized effectively in treating patients. Following these treatments, patients exhibited improved functioning, as evident in enhanced duration of
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.